drugset / Trial / NCT04358068
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
Phase 2
Terminated
20 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Teva Pharmaceutical Industries, Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
Timeline
- Start
- 2020-05-13
- Primary completion
- 2020-07-08
- Completion
- 2020-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 250 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 200 mg | Oral |